Valneva SE
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VALN research report →
Companyvalneva.com
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus.
- CEO
- Thomas Lingelbach
- IPO
- 2021
- Employees
- 713
- HQ
- Saint-Herblain, FR
Price Chart
Valuation
- Market Cap
- $527.22M
- P/E
- -3.10
- P/S
- 3.02
- P/B
- 5.59
- EV/EBITDA
- -6.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 29.46%
- Op Margin
- -68.81%
- Net Margin
- -88.30%
- ROE
- -106.22%
- ROIC
- -36.00%
Growth & Income
- Revenue
- $174.66M · 3.00%
- Net Income
- $-115,192,000 · -840.57%
- EPS
- $-1.32 · -656.88%
- Op Income
- $-81,631,000
- FCF YoY
- 31.42%
Performance & Tape
- 52W High
- $12.25
- 52W Low
- $5.06
- 50D MA
- $6.76
- 200D MA
- $8.91
- Beta
- 1.72
- Avg Volume
- 91.88K
Get TickerSpark's AI analysis on VALN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VALN Coverage
We haven't published any research on VALN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VALN Report →